Publications by authors named "Isabelle G Solman"
Article Synopsis
- - The study assessed immune cell subsets in CLL patients undergoing treatment with ibrutinib and venetoclax, revealing significant reductions in CLL cells and recovery of normal immune cell counts over time.
- - Patients with confirmed undetectable minimal residual disease (uMRD) showed similar immune cell levels to healthy donors after treatment, especially by cycle 16, while those without uMRD had slightly elevated levels.
- - The findings suggest that treatment with ibrutinib plus venetoclax not only eliminates CLL cells but also restores normal blood immune composition, highlighting its potential effectiveness in improving patient outcomes.
This study evaluated long-term immunophenotypic changes in circulating levels of 24 immune cell subsets through 4 years of continuous treatment with first-line ibrutinib (420 mg once daily) in 31 patients with chronic lymphocytic leukemia (CLL) from the RESONATE-2 study, and compared them with untreated age-matched healthy donors (n = 20). Ibrutinib progressively decreased total B-cell counts and preferentially targeted malignant CLL B cells over normal B cells. Elevated counts of chronically activated, exhausted, and effector memory T cells were normalized within 6-16 months, while naive T cells remained mostly within healthy donor range (HDR).
View Article and Find Full Text PDFIbrutinib positively modulates many T-cell subsets in chronic lymphocytic leukemia (CLL). To understand ibrutinib's effects on the broader landscape of immune cell populations, we comprehensively characterized changes in circulating counts of 21 immune blood cell subsets throughout the first year of treatment in patients with relapsed/refractory (R/R) CLL (n = 55, RESONATE) and previously untreated CLL (n = 50, RESONATE-2) compared with untreated age-matched healthy donors (n = 20). Ibrutinib normalized abnormal immune cell counts to levels similar to those of age-matched healthy donors.
View Article and Find Full Text PDFArticle Synopsis
- Certain genomic features, like del(11q) or complex karyotype, are linked to worse outcomes in chronic lymphocytic leukemia (CLL) patients receiving chemotherapy.
- A study analyzed long-term data from multiple clinical trials to assess the impact of these genomic markers on the effectiveness of ibrutinib, a targeted therapy, in 1,238 patients.
- The results showed that patients treated with ibrutinib had improved progression-free survival (PFS) regardless of genomic risk factors, and notably, those with del(11q) experienced longer PFS compared to those without it.
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Clin Lymphoma Myeloma Leuk
December 2018
Background: Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Patients And Methods: Measures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n = 195) or ofatumumab (n = 196) for up to 24 weeks. Endpoints included hematologic function, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), disease-related symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC QLQ-C30), and medical resource utilization.